Trial · NCT03520686
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686, Phase 3, Terminated, ImmunityBio, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer. Trials, record NCT03520686. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03520686
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
- NCT number
- NCT03520686
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 102 participants, actual
- Lead sponsor
- ImmunityBio, Inc.
- Conditions
- Non Small Cell Lung Cancer
- Interventions
NAI + Pembrolizumab, NAI + Nivolumab + Ipilimumab, NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI, Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI, Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI, Carboplatin + Nab-paclitaxel + Atezolizumab + NAI, Pembrolizumab, Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel, Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab, Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab, Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab, Carboplatin and Nab-paclitaxel plus Atezolizumab, Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel
- First posted
- 2018-05-11
- Last updated
- 2026-05-26
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | 24 Months | Defined by RECIST Version 1.1 based on BICR |
| Primary | Change in absolute lymphocyte count (ALC). | Significantly Higher ALC Values Over Time Between Experimental & Control Arms Through 27 Weeks | Change in absolute lymphocyte count (ALC) over time in participants treated with NAI in combination with approved CPI(s) |
| Secondary | Overall Survival (OS) | 24 Months | |
| Secondary | Overall Response Rate (ORR) | 24 Months | Defined by RECIST Version 1.1 based on BICR |
| Secondary | Duration of Response (DOR) | 24 Months | Defined by RECIST Version 1.1 based on BICR. |
| Secondary | PFS | 24 Months | Defined by iRECIST based on BICR. |
| Secondary | Overall Response Rate (ORR) | 24 Months | Defined by iRECIST based on BICR. |
| Secondary | Duration of Response (DOR) | 24 Months | Defined by iRECIST based on BICR. |
| Secondary | Disease Control Rate (DCR) | 2 Months | Confirmed CR, PR, or SD lasting for at least 2 months by RECIST Version 1.1 based on BICR |
| Secondary | Quality of Life based on Patient Reported Outcomes Questionnaires (Cohorts A, B, C only) | 24 Months | FACT-L |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03520686
GET https://conductscience.org/api/trials/v1/NCT03520686/registered